NexgenRx Inc. Stocks

$ 0.27Last Updated 29.04.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 19.20M

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.27
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. It offers prescription drug claims; dental claims; and claims for the extended health benefits, as well as a health care spending account that provides an amount of money to an individual to pay for health or dental benefits. The company also offers individual and aggregate stop loss products; medical emergency and travel assistance insurance services; administrative services, including the collection and payment of premiums for life and LTD coverage, as well as a suite of reporting tools; Web claims submission services; direct deposit services; and ancillary services. NexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, reasonably pr

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks